Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Jesse Boumelha, Mı́riam Molina-Arcas, Julian Downward
Clinical Cancer Research (2023) Vol. 29, Iss. 24, pp. 5012-5020
Open Access | Times Cited: 14

Showing 14 citing articles:

Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
Samir H. Barghout, Luna Jia Zhan, Starvroula Raptis, et al.
Lung Cancer (2024) Vol. 194, pp. 107898-107898
Closed Access | Times Cited: 6
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy
Violeta Delgado-Almenta, José L. Blaya-Cánovas, Jesús Calahorra, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 216-216
Open Access
Synthetic gene circuits that selectively target RAS-driven cancers
Gabriel Senn, Leon Nissen, Yaakov Benenson
(2025)
Open Access
Synthetic gene circuits that selectively target RAS-driven cancers
Gabriel Senn, Leon Nissen, Yaakov Benenson
(2025)
Open Access
The Challenging Scenario of Cancer Treatment for People with HIV: Clinical Experience with Immune Checkpoint Inhibitors
Tindara Franchina, Patrizia Carroccio, Ylenia Russotto, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 164-164
Open Access
Inactivation of Ymr1, Sjl2/3 phosphatases promotes stress resistance and longevity in wild type and Ras2G19V yeast
Mario G. Mirisola, Valter D. Longo
Biomedical Journal (2023) Vol. 47, Iss. 2, pp. 100694-100694
Open Access | Times Cited: 2
Differential landscape of immune evasion in oncogenic RAS-driven primary and metastatic colorectal cancers
Emil Lou, Joanne Xiu, Yasmine Baca, et al.
Deleted Journal (2024) Vol. 32, Iss. 1, pp. 200786-200786
Open Access
KRAS combination strategies: How well aligned is clinical and preclinical research?
Ernest Nadal, Chiara Ambrogio, David Santamarı́a, et al.
Elsevier eBooks (2024), pp. 417-441
Closed Access
Introduction
Shiva Malek, Frank McCormick
Elsevier eBooks (2024), pp. xxxvii-xlii
Closed Access
Introduction to RAS biology
Channing J. Der, Frank McCormick
Elsevier eBooks (2024), pp. 1-36
Closed Access
Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities
Yuting Li, Qinghua Wang, Xiaopan Gao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Synthetic gene circuits that selectively target RAS-driven cancers
Gabriel Senn, Leon Nissen, Yaakov Benenson
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top